NCT05939414 2026-04-16
PSMA-DC
Novartis
Phase 3 Recruiting
Clinical Trials
12 trialsNCT05249114 2026-04-13
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Phase 1 Active not recruiting
NCT05413850 2026-04-13
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
NCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
NCT06517719 2026-04-13
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Novartis
Recruiting
NCT06894511 2026-04-08
PSMAndARPI
Novartis
Phase 2 Active not recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT07145177 2026-03-23
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT06379217 2026-03-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT04711135 2026-02-12
NETTER-P
Advanced Accelerator Applications
Phase 2 Active not recruiting
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed